The role of inhibition of apoptosis in acute leukemias and myelodysplastic syndrome
A McBride, S Houtmann, L Wilde, C Vigil… - Frontiers in …, 2019 - frontiersin.org
A McBride, S Houtmann, L Wilde, C Vigil, CM Eischen, M Kasner, N Palmisiano
Frontiers in oncology, 2019•frontiersin.orgAvoidance of apoptosis is a key mechanism that malignancies, including acute leukemias
and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an
inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront
AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical data for
apoptosis inhibitors currently in development for the treatment of AML, ALL, and MDS.
and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an
inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront
AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical data for
apoptosis inhibitors currently in development for the treatment of AML, ALL, and MDS.
Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical data for apoptosis inhibitors currently in development for the treatment of AML, ALL, and MDS.
Frontiers以上显示的是最相近的搜索结果。 查看全部搜索结果